Chahoud Jad, Pham Rachel, Sonpavde Guru
Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas.
Curr Opin Urol. 2022 Jan 1;32(1):8-16. doi: 10.1097/MOU.0000000000000941.
The purpose of this review is to look at recent advancements and treatment options of systemic therapies to treat penile squamous cell carcinoma (PSCC). PSCC is a rare cancer that remains with limited funding for research and systemic therapy development. This review aims to discuss the most recent advancements in systemic treatments and our understanding of PSCC.
Neoadjuvant chemotherapy (NAC) and adjuvant therapy remain integral parts of treatment in locally advanced PSCC. New potential drug regimens are being studied to expand on the availability of first-line regimen options. There has been a large development in discoveries of cellular pathways and immune system targets as potential treatment options but these therapies as of today have limited trial evidence and currently have no support to be used in a clinical setting.
PSCC is a rare genitourinary cancer with limited treatment options for patients with advanced disease that is refractory to chemotherapy. Although many new therapies targeting the immune system and cellular pathways are being developed for other studies, clinical and translational research for PSCC are still understudied and underfunded.
本综述旨在探讨治疗阴茎鳞状细胞癌（PSCC）的全身治疗的最新进展和治疗选择。PSCC是一种罕见的癌症，其研究资金和全身治疗开发仍然有限。本综述旨在讨论全身治疗的最新进展以及我们对PSCC的认识。
新辅助化疗（NAC）和辅助治疗仍然是局部晚期PSCC治疗的重要组成部分。正在研究新的潜在药物方案，以扩大一线方案的选择范围。作为潜在治疗选择的细胞途径和免疫系统靶点的发现有了很大进展，但截至目前，这些疗法的试验证据有限，目前在临床环境中尚无应用支持。
PSCC是一种罕见的泌尿生殖系统癌症，对于化疗难治的晚期患者，治疗选择有限。尽管针对免疫系统和细胞途径的许多新疗法正在为其他研究而开发，但PSCC的临床和转化研究仍未得到充分研究且资金不足。
